BioSynaptica
1 known investors
Find your way into BioSynaptica
Sign up to see every warm intro you have to BioSynaptica
- Paths you didn't know you had: your email and LinkedIn already hold routes to the BioSynaptica team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
BioSynaptica is a biopharmaceutical startup developing an innovative neurodrug derived from modified human erythropoietin (hEPO) to treat neurodegenerative conditions such as Parkinson's, Alzheimer's, multiple sclerosis, neurotrauma, and degenerative retinopathies. Its technology alters the hEPO molecule to remove unwanted erythropoietic side effects while preserving neuroprotective and neuroplastic activity, demonstrated in vivo.
Founders & leadership
MD
Matías DepetrisDirector
MB
Milagros Bürgi
RK
Ricardo Kratje
MO
Marcos Oggero Eberhardt
Investors · 1
Frequently asked questions
- What does BioSynaptica do?
- BioSynaptica is a biopharmaceutical startup developing an innovative neurodrug derived from modified human erythropoietin (hEPO) to treat neurodegenerative conditions such as Parkinson's, Alzheimer's, multiple sclerosis, neurotrauma, and degenerative retinopathies. Its technology alters the hEPO molecule to remove unwanted erythropoietic side effects while preserving neuroprotective and neuroplastic activity, demonstrated in vivo.
- Who are BioSynaptica's investors?
- BioSynaptica's investors include Aceleradora Litoral.